Proposed Removal of Prescriptive Rule on Indirect Vehicle Loan Servicing

The NCUA Board published a proposed rule to remove prescriptive regulatory requirements governing third-party servicing of indirect vehicle loans currently codified at §§ 701.21(h) and 741.203(c). The existing rule limits indirect loans and participations purchased from any one servicer to 50% of a credit union's net worth (increasing to 100% after 30 months of experience). The proposal seeks comment on reducing regulatory burden and providing credit unions greater operational flexibility through a principles-based supervisory approach.

Generic Omeprazole Oral Paste Approved for Horse Gastric Ulcers

The FDA approved Gastrobim (omeprazole) oral paste as a generic equivalent to Gastrogard for the treatment and prevention of gastric ulcers in horses and foals four weeks of age and older. Sponsored by Bimeda Animal Health Ltd. of Ireland, the drug was determined bioequivalent to the brand-name product approved in 1999. Gastrobim is available only by prescription from a licensed veterinarian.

PROSECCO Trial: Cemiplimab Combination for Melanoma

ClinicalTrials.gov registered a new Phase III trial (NCT07511036) called PROSECCO, studying cemiplimab in combination therapy for melanoma. The trial is sponsored by Regeneron Pharmaceuticals and is currently listed as not recruiting. Cemiplimab is a PD-1 inhibitor marketed as Libtayo.

Clinical trial page for NCT07511049

Clinical trial page for NCT07511049

MEND II mindfulness neurostimulation for depression, UC San Diego

The National Library of Medicine registered a new clinical trial, NCT07512284, on ClinicalTrials.gov. The MEND II study will investigate mindfulness neurostimulation as an intervention for depression at UC San Diego.

Precision radiotherapy, molecular MRI, brain cancer, Johns Hopkins

The National Library of Medicine registered clinical trial NCT07512154 on ClinicalTrials.gov. The trial, sponsored by Johns Hopkins University, studies precision radiotherapy combined with molecular MRI for brain cancer. This registration fulfills requirements under 42 U.S.C. §282 for federally funded clinical trials to be publicly registered.

AML clinical trial investigating TP53 mutation treatment

The National Library of Medicine registered a new clinical trial on ClinicalTrials.gov (NCT07511062) investigating treatment for TP53 mutations in Acute Myeloid Leukemia (AML) patients. This is an informational registry entry providing public access to trial information as required under federal clinical trial registration requirements.

Sacituzumab tirumotecan Phase 2 anal/rectal cancer trial

The National Library of Medicine registered a new Phase 2 clinical trial (NCT07511023) on ClinicalTrials.gov evaluating sacituzumab tirumotecan for the treatment of anal and rectal cancer. The single-arm study will enroll participants with metastatic or locally advanced disease. This trial registration provides public transparency on an ongoing cancer immunotherapy study.

AZD1043 Safety Study - AstraZeneca/Parexel

The National Library of Medicine updated ClinicalTrials.gov to add a new Phase 1 safety study for AZD1043 sponsored by AstraZeneca and Parexel. The trial is listed as 'not recruiting.' Clinical investigators and pharmaceutical sponsors should ensure their trials are properly registered.

VDBD Treatment Clinical Trial NCT07513129

The National Library of Medicine registered clinical trial NCT07513129 on ClinicalTrials.gov to study VDBD treatment. The trial is now publicly accessible in the clinical trials database.